Insider Selling: Taysha Gene Therapies (NASDAQ:TSHA) Insider Sells 89,132 Shares of Stock

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) insider Sukumar Nagendran sold 89,132 shares of the business’s stock in a transaction that occurred on Friday, January 23rd. The shares were sold at an average price of $4.75, for a total value of $423,377.00. Following the completion of the transaction, the insider directly owned 1,344,307 shares in the company, valued at approximately $6,385,458.25. The trade was a 6.22% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

Sukumar Nagendran also recently made the following trade(s):

• On Monday, January 26th, Sukumar Nagendran sold 26,918 shares of Taysha Gene Therapies stock. The stock was sold at an average price of $4.61, for a total transaction of $124,091.98.
• On Monday, January 12th, Sukumar Nagendran sold 200,000 shares of Taysha Gene Therapies stock. The shares were sold at an average price of $4.71, for a total value of $942,000.00.
• On Friday, November 28th, Sukumar Nagendran sold 110,125 shares of Taysha Gene Therapies stock. The stock was sold at an average price of $4.75, for a total transaction of $523,093.75.
• On Monday, December 1st, Sukumar Nagendran sold 260,047 shares of Taysha Gene Therapies stock. The stock was sold at an average price of $4.51, for a total value of $1,172,811.97.

Taysha Gene Therapies Stock Up 0.8%

NASDAQ TSHA traded up $0.04 on Tuesday, reaching $4.76. The stock had a trading volume of 1,384,585 shares, compared to its average volume of 2,812,476. The business has a 50 day moving average price of $5.08 and a 200 day moving average price of $4.07. The company has a current ratio of 10.48, a quick ratio of 10.48 and a debt-to-equity ratio of 0.23. Taysha Gene Therapies, Inc. has a 1 year low of $1.05 and a 1 year high of $6.02. The company has a market capitalization of $1.30 billion, a price-to-earnings ratio of -14.42 and a beta of 1.02.

Taysha Gene Therapies (NASDAQ:TSHA) last announced its earnings results on Tuesday, November 4th. The company reported ($0.09) EPS for the quarter, hitting the consensus estimate of ($0.09). Taysha Gene Therapies had a negative return on equity of 67.26% and a negative net margin of 1,144.97%. On average, analysts forecast that Taysha Gene Therapies, Inc. will post -0.35 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on TSHA. Wall Street Zen lowered shares of Taysha Gene Therapies from a “hold” rating to a “sell” rating in a research report on Saturday, January 3rd. Citizens Jmp boosted their target price on shares of Taysha Gene Therapies from $6.00 to $8.00 and gave the stock a “market outperform” rating in a report on Wednesday, November 5th. The Goldman Sachs Group set a $11.00 price objective on shares of Taysha Gene Therapies in a report on Thursday, December 4th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Taysha Gene Therapies in a report on Monday, December 29th. Finally, Needham & Company LLC restated a “buy” rating and set a $10.00 price target on shares of Taysha Gene Therapies in a research report on Friday, October 17th. One analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $10.67.

Hedge Funds Weigh In On Taysha Gene Therapies

Institutional investors and hedge funds have recently bought and sold shares of the business. Marex Group plc bought a new position in shares of Taysha Gene Therapies in the second quarter valued at approximately $29,000. E Fund Management Co. Ltd. purchased a new position in shares of Taysha Gene Therapies in the second quarter worth about $31,000. ST Germain D J Co. Inc. lifted its holdings in Taysha Gene Therapies by 81.8% in the 3rd quarter. ST Germain D J Co. Inc. now owns 9,633 shares of the company’s stock worth $32,000 after buying an additional 4,333 shares during the period. May Hill Capital LLC bought a new position in shares of Taysha Gene Therapies in the 2nd quarter worth approximately $37,000. Finally, Arrowpoint Investment Partners Singapore Pte. Ltd. purchased a new position in Taysha Gene Therapies during the third quarter valued at $40,000. Hedge funds and other institutional investors own 77.70% of the company’s stock.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.